Compare Deckers Outdoor Corp (DECK) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Mesoblast Limited — how do they compare? Deckers Outdoor Corp trades at $82.76 (market cap $11.24B), while Mesoblast Limited trades at $14.34 (market cap $1.75B). The key difference: Deckers Outdoor Corp is far larger — about 6.4× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 3,010,945). Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Mesoblast Limited for 14 Days on average.
| DECK | MESO | |
|---|---|---|
Market Cap | $11.24B | $1.75B |
Volume | 3,010,945 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $20.96 |
52-Week Low | $77.51 | $13.19 |
Typical Hold Time | 71 Days | 14 Days |
Enterprise Value | $10.11B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers (DECK) trades at $82.15, up 2.2% with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats, 19.4% net margin, and robust revenue growth from $3.2B in 2022 to $5.0B in 2025. Recent news highlights HOKA and UGG brand momentum driving investor optimism. Technical indicators show the stock trading near resistance at $82 with support at $79.
DECK presents compelling value with a P/E of 11.7x below industry averages and analyst consensus target of $117 suggesting 43% upside. Risks include competitive pressures in footwear and potential macroeconomic headwinds affecting consumer discretionary spending. The strong cash flow generation and brand strength support continued growth potential.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
